Chen, Xi
Zhang, Jiaqi
Pan, Maohua
Qin, Yucheng
Zhao, Hui
Qin, Pien
Yang, Qi
Li, Xinxin
Zeng, Weilin
Xiang, Zheng
Duan, Mengxi
Li, Xiaosong
Wang, Xun
Mazier, Dominique
Zhang, Yanmei
Zhao, Wei
Rosenthal, Benjamin M.
Huang, Yaming
Yang, Zhaoqing
Funding for this research was provided by:
National Science Foundation of China (31860604, U1802286)
Major science and technology projects of Yunnan Province (2018ZF0081)
International Science and Technology Cooperation-Yunnan International Science and Technology Cooperation Base (202003AE140004)
Yunnan Applied Basic Research Projects-Union Foundation (2018FE001-190, 2019FE001-015)
Guangxi Zhuang Autonomous Region Health Commission of Scientific Research Project (Z20190892)
Education Department Fund of Yunnan Province (2019J1184)
Article History
Received: 9 December 2020
Accepted: 3 May 2021
First Online: 24 May 2021
Declarations
:
: We used clinical samples obtained from the Department of Infectious Diseases in Shanglin Hospital, Shanglin County, Guangxi Province, China and from the Malaria surveillance clinic, Tengchong County (China–Myanmar border), Yunnan Province, China. The clinical subjects were Chinese migrant workers who had returned from Africa or Myanmar. This study was approved by the Ethics Review Committees of Institutional Review Board (IRB) of Shanglin Hospital and Institutional Review Board of Kunming Medical University, Yunnan Province, China. All participants provided written informed consent: written informed consent was obtained from either the patients themselves or from the guardians of patients who were minors at the time of the study.
: Not applicable.
: The authors affirm that they have no conflict of interest. The novel primers of malaria Pan <i>mtDNA</i> LAMP, 1<i>8S rDNA P. vivax</i> and <i>18S rDNA P. ovale</i> LAMP in our assay were included in Patent No: 201910611312.9 (China), citing XC, JZ, and ZY as inventors.